APA (7th ed.) Citation

Akira Utsunomiya, Noritaka Oyama, Shiro Iino, Natsuki Baba, Takenao Chino, Natsuko Utsunomiya, & Minoru Hasegawa. (2018). A Case of Erythema Multiforme Major Developed after Sequential Use of Two Immune Checkpoint Inhibitors, Nivolumab and Ipilimumab, for Advanced Melanoma: Possible Implication of Synergistic and/or Complementary Immunomodulatory Effects. Karger Publishers.

Chicago Style (17th ed.) Citation

Akira Utsunomiya, Noritaka Oyama, Shiro Iino, Natsuki Baba, Takenao Chino, Natsuko Utsunomiya, and Minoru Hasegawa. A Case of Erythema Multiforme Major Developed After Sequential Use of Two Immune Checkpoint Inhibitors, Nivolumab and Ipilimumab, for Advanced Melanoma: Possible Implication of Synergistic And/or Complementary Immunomodulatory Effects. Karger Publishers, 2018.

MLA (9th ed.) Citation

Akira Utsunomiya, et al. A Case of Erythema Multiforme Major Developed After Sequential Use of Two Immune Checkpoint Inhibitors, Nivolumab and Ipilimumab, for Advanced Melanoma: Possible Implication of Synergistic And/or Complementary Immunomodulatory Effects. Karger Publishers, 2018.